The earth from space



Orikami completes Proof of Concept phase on track to personalize lung cancer patient journey.

· 1 min read

Elderly lung cancer patients are often over and undertreated due to the combination of standard treatment protocols in a highly heterogeneous patient population and the lack of a widely adopted monitoring solution to balance treatment effectiveness with quality of life.

In 2022, Orikami started, supported by Amgen Netherlands, a 3-year program to develop a digital biomarker tool for patients and physicians enabling them to remotely monitor a patient’s frailty and resilience. After the needs and wishes of patients and physicians were explored in the initial Discovery phase, we developed a first version of the product in the Proof of Concept phase. Currently, Orikami prepares a next version of the product to start collecting real world evidence in the upcoming validation studies.

Curious to learn more? Please visit this interview about the program here: